Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CANF
Stock Latest News
Company Announcements
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
3d ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
9d ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
9d ago
CANF
Premium
Company Announcements
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
17d ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
17d ago
CANF
Premium
The Fly
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
21d ago
CANF
Premium
Company Announcements
Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial
22d ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
22d ago
CANF
Premium
Company Announcements
Can-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology
27d ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
27d ago
CANF
Premium
Company Announcements
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
1M ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
1M ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting
2M ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
2M ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
2M ago
6K
CANF
Premium
Company Announcements
Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
2M ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
2M ago
CANF
Premium
Company Announcements
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
2M ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
2M ago
CANF
Premium
Company Announcements
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
3M ago
6K
CANF
Premium
Company Announcements
Can-Fite BioPharma Sets May 28, 2026 AGM to Vote on Share Capital Increase and Executive Option Grants
3M ago
6K
CANF
Premium
The Fly
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
4M ago
CANF
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
